Literature DB >> 2226400

Ultrastructural findings in horses with chronic obstructive pulmonary disease (COPD). II: Pathomorphological changes of the terminal airways and the alveolar region.

F J Kaup1, W Drommer, S Damsch, E Deegen.   

Abstract

Extensive light and electron microscope studies (transmission and scanning electron microscopy) of the bronchioles and alveolar region, in 28 horses suffering chronic obstructive pulmonary disease (COPD) and eight control horses, revealed good correlation between clinical severity and morphological changes. In the bronchiolar epithelium the non-ciliated bronchiolar epithelial (Clara) cells, in particular, showed ultrastructural alterations and, even in the mild stages of disease, these presented degenerative changes and lack of differentiation. Together with loss of granulation in the Clara cells and metaplasia of the goblet cells, cells were seen with unusual intracytoplasmic lamellar inclusion, the number of which increased sharply with clinical severity. The focal changes in the alveolar region were necrosis of type I epithelial cells, alveolar fibrosis of varying degrees with type II epithelial transformation and emphysema or hyperinflation, with an increase in Kohn's pores. Some horse also showed morphological signs of interference with the surfactant system, in the form of marked cysts with lamellar structure. The alveolar changes were mostly in the peribronchiolar region and were, therefore, interpreted as reactive processes. No conclusions as to the aetiology of equine COPD can be derived from these morphological investigations.

Entities:  

Mesh:

Year:  1990        PMID: 2226400     DOI: 10.1111/j.2042-3306.1990.tb04288.x

Source DB:  PubMed          Journal:  Equine Vet J        ISSN: 0425-1644            Impact factor:   2.888


  8 in total

1.  Questionnaire assessment of airway disease symptoms in equine barn personnel.

Authors:  Melissa R Mazan; Jessica Svatek; Louise Maranda; David Christiani; Andrew Ghio; Jenifer Nadeau; Andrew M Hoffman
Journal:  Occup Med (Lond)       Date:  2009-02-17       Impact factor: 1.611

2.  Chronic obstructive pulmonary disease: Usefulness of clinical signs, bronchoalveolar lavage, and lung biopsy as diagnostic and prognostic aids.

Authors:  J M Naylor; E G Clark; H M Clayton
Journal:  Can Vet J       Date:  1992-09       Impact factor: 1.008

Review 3.  Pulmonary Remodeling in Equine Asthma: What Do We Know about Mediators of Inflammation in the Horse?

Authors:  Ann Kristin Barton; Heidrun Gehlen
Journal:  Mediators Inflamm       Date:  2016-12-07       Impact factor: 4.711

4.  The pulmonary surfactant: impact of tobacco smoke and related compounds on surfactant and lung development.

Authors:  J Elliott Scott
Journal:  Tob Induc Dis       Date:  2004-03-15       Impact factor: 2.600

5.  Chlamydophila spp. infection in horses with recurrent airway obstruction: similarities to human chronic obstructive disease.

Authors:  Dirk Theegarten; Konrad Sachse; Britta Mentrup; Kerstin Fey; Helmut Hotzel; Olaf Anhenn
Journal:  Respir Res       Date:  2008-01-29

6.  Evaluation of amniotic mesenchymal cell derivatives on cytokine production in equine alveolar macrophages: an in vitro approach to lung inflammation.

Authors:  Enrica Zucca; Emanuela Corsini; Valentina Galbiati; Anna Lange-Consiglio; Francesco Ferrucci
Journal:  Stem Cell Res Ther       Date:  2016-09-20       Impact factor: 6.832

7.  Metalloproteinases and their inhibitors are influenced by inhalative glucocorticoid therapy in combination with environmental dust reduction in equine recurrent airway obstruction.

Authors:  Ann Kristin Barton; Tarek Shety; Angelika Bondzio; Ralf Einspanier; Heidrun Gehlen
Journal:  BMC Vet Res       Date:  2016-12-09       Impact factor: 2.741

8.  Flow cytometric analysis of equine bronchoalveolar lavage fluid cells in horses with and without severe equine asthma.

Authors:  Heng Kang; Dorothee Bienzle; Gary Kwok Cheong Lee; Érica Piché; Laurent Viel; Solomon Olawole Odemuyiwa; Janet Beeler-Marfisi
Journal:  Vet Pathol       Date:  2021-09-14       Impact factor: 2.221

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.